These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15106033)

  • 1. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children.
    Schüepp KG; Devadson S; Roller C; Wildhaber JH
    Swiss Med Wkly; 2004 Apr; 134(13-14):198-200. PubMed ID: 15106033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosol delivery of nebulised budesonide in young children with asthma.
    Schueepp KG; Devadason SG; Roller C; Minocchieri S; Moeller A; Hamacher J; Wildhaber JH
    Respir Med; 2009 Nov; 103(11):1738-45. PubMed ID: 19540100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalation of aerosols by children: an ongoing controversy.
    Schöni MH
    Swiss Med Wkly; 2004 Apr; 134(13-14):173-4. PubMed ID: 15106030
    [No Abstract]   [Full Text] [Related]  

  • 4. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
    Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
    Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung deposition of budesonide from the novel dry powder inhaler Airmax.
    Hirst RH; Newman SR; Clark DA; Hertog MG
    Respir Med; 2002 Jun; 96(6):389-96. PubMed ID: 12117037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much nebulised budesonide reaches infants and toddlers?
    Lødrup Carlsen KC; Nikander K; Carlsen KH
    Arch Dis Child; 1992 Sep; 67(9):1077-9. PubMed ID: 1417048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhalers and nebulizers in the children].
    David V; Mély L; Siret D; Dubus JC
    Arch Pediatr; 2002 Aug; 9 Suppl 3():415s-421s. PubMed ID: 12205818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro.
    Meindl C; Stranzinger S; Dzidic N; Salar-Behzadi S; Mohr S; Zimmer A; Fröhlich E
    PLoS One; 2015; 10(8):e0135690. PubMed ID: 26274590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scintigraphic evaluation of lung deposition with a novel inhaler device.
    Newman SP; Hirst PH; Pitcairn GR
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S12-4. PubMed ID: 11385810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!
    Amirav I; Balanov I; Gorenberg M; Groshar D; Luder AS
    Arch Dis Child; 2003 Aug; 88(8):719-23. PubMed ID: 12876173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique.
    Warren S; Taylor G; Smith J; Buck H; Parry-Billings M
    J Aerosol Med; 2002; 15(1):15-25. PubMed ID: 12006142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung deposition of inhaled drugs increases with age.
    Onhøj J; Thorsson L; Bisgaard H
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1819-22. PubMed ID: 11069819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in pediatric aerosol delivery: importance of facemask.
    Smaldone GC; Berg E; Nikander K
    J Aerosol Med; 2005; 18(3):354-63. PubMed ID: 16181009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
    Pitcairn G; Reader S; Pavia D; Newman S
    J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
    Brand P; Hederer B; Austen G; Dewberry H; Meyer T
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of flow pattern, device and formulation on particle size distribution of nebulized aerosol.
    Hu J; Zhang R; Beng H; Deng L; Ke Q; Tan W
    Int J Pharm; 2019 Apr; 560():35-46. PubMed ID: 30664994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical ventilation.
    Pornputtapitak W; El-Gendy N; Mermis J; O'Brien-Ladner A; Berkland C
    Int J Pharm; 2014 Feb; 462(1-2):19-28. PubMed ID: 24374223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic availability of Rhinocort Aqua (budesonide) nasal spray: importance of formulation and definition of delivered dose.
    O'Dowd L; Thorsson L; Edsbacker S
    J Allergy Clin Immunol; 2002 Jun; 109(6):1037; author reply 1037-8. PubMed ID: 12063539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.